Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anagliptin - Sanwa Kagaku Kenkyusho/Kowa Pharmaceutical

Drug Profile

Anagliptin - Sanwa Kagaku Kenkyusho/Kowa Pharmaceutical

Alternative Names: Beskoa; CWP-0403; SK-0403; Suiny

Latest Information Update: 08 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko; Sanwa Kagaku Kenkyusho
  • Developer JW Pharmaceutical; Kowa Pharmaceutical; Sanwa Kagaku Kenkyusho
  • Class Antihyperglycaemics; Nitriles; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 05 Mar 2019 No development reported - Phase-III for Type 2 diabetes mellitus in South Korea (PO)
  • 04 Mar 2019 Anagliptin is still in phase II trials for Type 2 diabetes mellitus in USA and EU (Kowa Pharmaceutical pipeline, March 2019)
  • 21 Nov 2018 Sanwa Kagaku Kenkyusho and Yokohama City University complete a phase II trial for Type 2 diabetes mellitus in Japan (PO) (UMIN000021494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top